

CURRICULUM VITAE



Eric Jon Kort, M.S., M.D.
Praxis Med Experts
expert@praxismedexperts.com
628-600-3589

Certifications

Board Certified in Pediatric Hospitalist Medicine (American Board of Pediatrics)

Pediatric Advanced Life Support (American Heart Association, last renewed May, 2023)

Neonatal Resuscitation Program (American Academy of Pediatrics, last renewed March, 2024)

Professional experience & Post-Graduate Training

- 2012-Present Pediatric Hospitalist, Spectrum Health Medical Group/Helen DeVos Children's Hospital
- 2015-Present Clinical Assistant Professor, Pediatrics & Human Development, Michigan State University
- 2024-Present Founder & CEO, Intent Pharmaceuticals (www.intentpharma.org)
- 2015-2022 Research Scientist, DeVos Cardiovascular Research program of Spectrum Health and Van Andel Research Institute
- 2013-2015 Clinical Instructor, Department of Pediatrics and Human Development, MSU
- 2009-2012 Pediatric Resident, Helen DeVos Children's Hospital/Michigan State University.
- 2006-2009 Post-doctoral fellow/Research Scientist, Van Andel Research Institute.
- 2002-2006 Bioinformatics & Statistical Analyst, Van Andel Research Institute, Laboratory of Cancer Genetics.
- 2000-2002 Visiting Scientist/Senior Epidemiologist/Bioinformatics & Statistical Analyst, Van Andel Research Institute, Laboratory of Analytical, Cellular and Molecular Microscopy, Grand Rapids, Michigan.

Professional activities

1. *Chair, Pediatric Medical Staff Performance Committee, 2021-2023 (Corewell Health, Helen DeVos Children's Hospital)*
2. *Chair, Institutional Review Board, 2022-2023*
3. *Moderator, AAP Pediatric Hospitalist Medicine LISTSERV®, 2021-2023.*

Education

- 1992-1997 Calvin College, Grand Rapids, Michigan. B.A. (Philosophy) Honors:
- National Merit Scholar
- 1997-2000 Michigan State University, East Lansing, Michigan. M.S. (Epidemiology)
- 2001-2006 Michigan State University. M.D.
Honors:
- Alpha Omega Alpha Honors Medical Society Inductee.
 - Honors designation in Surgery, Obstetrics and Gynecology, and Family Medicine Clerkships.
 - Co-author on paper/presentation receiving “Best Resident Physician Paper Presentation” award at MERC Research Day, 2006.

Peer-reviewed publications

1. Paneth N, **Kort EJ**, Jurczak D, Havlichek DA Jr, Braunlich K, Moorer G, Vanderjagt D, Sienko D, Leiby P, Gibbons C: Predictors of vaccination rates during a mass meningococcal vaccination program on a college campus. *J Am Coll Health*, 2000;49:7-11.
2. Cao B, Su Y, Oskarsson M, Zhao P, **Kort EJ**, Fisher RJ, Wang LM, Vande Woude GF: Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. *Proc Natl Acad Sci U S A*. 2001, 98:7443-8.
3. Qian CN, Guo X, Cao B, **Kort EJ**, Lee CC, Chen J, Wang LM, Mai WY, Min HQ, Hong MH, Vande Woude GF, Resau JH, Teh BT: Met protein expression level correlates with survival in patients with latestage nasopharyngeal carcinoma. *Cancer Res*, 2002;62:589-96.
4. Lui WO, Chen J, Glasker S, Bender BU, Madura C, Khoo SK, **Kort EJ**, Larsson C, Neumann HP, Teh BT: Selective loss of chromosome 11 in pheochromocytomas associated with the VHL syndrome. *Oncogene*, 2002;21:1117-22.
5. **Kort EJ**, Campbell B, Resau J. A human tissue & data resource: an overview of opportunities, challenges, and development of a provider/researcher partnership model. *Comput Methods Programs Biomed*, 2002;70(2):137-50.
6. **Kort EJ**, Jones A, Daumbach M, Hudson EA, Buckner B, Resau JH. Quantifying cell scattering: The blob algorithm revisited. *Cytometry*, 2003;51(A)2:119-26.
7. **Kort EJ**, Moore MR, Hudson EA, Leeser B, Yeruhalmi GM, Leibowitz-Amit R, Tsarfaty G, Tsarfaty T, Moshkovitz S, Resau JH. Use of Organ Explant and Cell Culture in Mechanisms of Carcinogenesis. 2006, Kluwer Academic Publishers: Dordrecht, Netherlands.
8. Furge KA, Lucas KA, Takahashi M, Sugimura J, **Kort EJ**, Kanayama HO, Kagawa S, Hoekstra P, Curry J, Yang XJ, Teh BT. Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. *Cancer Res*. 2004 Jun 15;64(12):4117-21.
9. Sugimura J, Foster RS, Cummings OW, **Kort EJ**, Takahashi M, Lavery TT, Furge KA, Einhorn LH, Teh BT. Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. *Clin Cancer Res*. 2004 Apr 1;10(7):2368-78.

10. Sugimura J, Yang XJ, Tretiakova MS, Takahashi M, **Kort EJ**, Fulton B, Fujioka T, Vogelzang NJ, Teh BT. Gene expression profiling of mesoblastic nephroma and Wilms tumors--comparison and clinical implications. *Urology*. 2004 Aug;64(2):362-8; discussion 368.
11. Takahashi M, Papavero V, Yuhas J, **Kort E**, Kanayama HO, Kagawa S, Baxter RC, Yang XJ, Gray SG, Teh BT. Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. *Int J Oncol*. 2005 Apr;26(4):923-31.
12. Akervall J, Guo X, Qian CN, Schoumans J, Leeser B, **Kort E**, Cole A, Resau J, Bradford C, Carey T, Wennerberg J, Anderson H, Tennvall J, Teh BT. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. *Clin Cancer Res*. 2004 Dec 15;10(24):8204-13.
13. Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, **Kort EJ**, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT. A molecular classification of papillary renal cell carcinoma. *Cancer Res*. 2005 Jul 1;65(13):5628-37.
14. Diaz VM, Hurtado M, **Kort EJ**, Resnati M, Blasi F, Thomson T, Paciucci R. Requirement of the enzymatic and signaling activities of plasmin for phorbol-ester-induced scattering of colon cancer cells. *Exp Cell Res*. 2006 Jul 15;312(12):2203-13.
15. Qian CN, Berghuis B, Tsarfaty G, Bruch MB, **Kort EJ**, Ditlev J, Tsarfaty I, Hudson E, Jackson DG, Petillo D, Chen J, Resau JH, Teh BT. Preparing the "soil": The primary tumor induces vasculature reorganization in the sentinel lymph node prior to the arrival of metastatic cancer cells. *Cancer Res*. 2006;66(21):10356-76.
16. Yao X, Qian CN, Zhang ZF, Tan MH, **Kort EJ**, Yang XJ, Resau JH, Teh BT. Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. *Clin Cancer Res*. 2007 Jan 1;13(1):161-9.
17. Baldus SE, **Kort EJ**, Schirmacher P, Dienes HP, Resau JH. Quantification of MET and hepatocyte growth factor/scatter factor expression in colorectal adenomas, carcinomas and nonneoplastic epithelia by quantitative laser scanning microscopy. *Int J Oncol*. 2007 Jul;31(1):199-204.
18. Furge KA, **Kort EJ**, Yang XJ, Stadler WM, Kim H, Teh BT. Gene expression profiling in kidney cancer: combining differential expression and chromosomal and pathway analyses. *Clin Genitourin Cancer*. 2006 Dec;5(3):227-31.
19. Furge KA, Tan MH, Dykema K, **Kort E**, Stadler W, Yao X, Zhou M, Teh BT. Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. *Oncogene*. 2007 Feb 26;26(9):1346-50.
20. Depeille P, Young JJ, Boguslawski EA, Berghuis BD, **Kort EJ**, Resau JH, Frankel AE, Duesbery NS. Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor. *Clin Cancer Res*. 2007 Oct 1;13(19):5926-34.
21. Lindemann K, Resau J, Nährig J, **Kort E**, Leeser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck N. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. *Histopathology*. 2007 Jul;51(1):54-62.

22. Furge KA, Dykema K, Petillo D, Westphal M, Zhang Z, **Kort EJ**, Teh BT. Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma. *Can Urol Assoc J.* 2007 Jun;1(2 Suppl):S21-7
23. Yang WJ, Hes O, Li R, Shah RB, Chuang ST, Tretiakova MM, **Kort EJ**, Teh BT. Tubulocystic Carcinoma of the Kidney—Clinicopathological and Molecular Characterization. *Am J Pathol.* 2008 Feb;32(2):177-187.
24. Huang D, Ding Y, Luo WM, Bender S, Qian CN, **Kort E**, Zhang ZF, VandenBeldt K, Duesbery NS, Resau JH, Teh BT. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. *Cancer Res.* 2008 Jan 1;68(1):81-8.
25. Fitzgerald TL, Hickner ZJ, Schmitz M, **Kort EJ**. Changing incidence of pancreatic neoplasms: a 16 year review of statewide tumor registry data. *Pancreas.* 2008 Aug;37(2):134-8.
26. Haak PB, Busik JV, **Kort EJ**, Tikhonenko M, Paneth N, Resau, JH. Archived unfrozen neonatal blood spots are amenable to quantitative gene expression analysis. *Neonatology.* 2008 Sep 18;95(3):210-216.
27. **Kort EJ**, Farber L, Tretiakova M, Petillo D, Furge KA, Yang X, Cornelius A, The BT. The E2F3—Oncomir 1 axis is activated in Wilms Tumor. *Cancer Research.* 2008;68 4034-4038.
28. Koeman JM, Russell RC, Tan MH, Petillo D, Westphal M, Koelzer K, Metcalf JL, Zhang Z, Matsuda D, Dykema KJ, Houseman HL, **Kort EJ**, Furge LL, Kahnoski RJ, French Kidney Cancer Consortium, Swiatek PJ, The BT, Ohh M, Furge KA. Somatic pairing of Chromosome 19 in renal oncocytoma is associated with deregulated ELGN2-mediated oxygen sensing response. *PLoS Genetics.* 2008 Sep 5;4(9):e1000176.
29. Rogers CG, Ditlev JA, Tan MH, Sugimura J, Qian CN, Cooper J, Jewett MAS, Kahnoski RJ, **Kort EJ**, Teh BT. Microarray gene expression profiling using core biopsies of renal neoplasia. *Am J Transl Med.* In Press.
30. **Kort EJ**, Paneth N, Vande Woude GF. The decline in U.S. cancer mortality in people born since 1925. *Cancer Res.* 2009 Aug 15;69(16):6500-5.
31. Qian CN, Furge KA, Knol J, Huang D, Chen J, Dykema KJ, **Kort EJ**, Massie A, Khoo SK, Vanden Beldt K, Resau JH, Anema J, Kahnoski RJ, Morreau H, Camparo P, Comperat E, Sibony M, Denoux Y, Molinie V, Vieillefond A, Eng C, Williams BO, Teh BT. Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. *Cancer Res.* 2009 Nov 1;69(21):8256-64. Epub 2009 Oct 20.
32. Petillo D, **Kort EJ**, Anema J, Furge KA, Yang XJ, Teh BT. MicroRNA profiling of human kidney cancer subtypes. *Int J Oncol.* 2009 Jul;35(1):109-14.
33. **Kort EJ**, Sevensma E, Fitzgerald TL. Trends in esophageal cancer and body mass index by race and gender in the state of Michigan. *BMC Gastroenterol.* 2009 Jun 23;9:47.
34. Farber LJ, **Kort EJ**, Wang P, Chen J, Teh BT. The tumor suppressor parafibromin is required for posttranscriptional processing of histone mRNA. *Mol Carcinog.* 2010 Mar;49(3):215-23.
35. Rogers CG, Ditlev JA, Tan MH, Sugimura J, Qian CN, Cooper J, Lane B, Jewett MA, Kahnoski RJ, **Kort EJ**, Teh BT. Microarray gene expression profiling using core biopsies of renal neoplasia. *Am J Transl Res.* 2009 Jan 1;1(1):55-61.

36. Yang Y*, **Kort EJ***, Ebrahimi N, Zhang Z, Teh BT. Dual KS: Defining Gene Sets with Tissue Set Enrichment Analysis. *Cancer Inform.* 2010 Jan 21;9:1-9.
37. Bromberg-White JL, Boguslawski E, Hekam D, **Kort E**, Duesbury NS. Persistent inhibition of oxygen induced retinal neovascularization by anthrax lethal toxin. *Invest Ophthalmol Vis Sci.* 2011 Nov 21;52(12):8979-92.
38. Tan MH, Wong CF, Tan HL, Yang XJ, Ditlev J, Matsuda D, Khoo SK, Sugimura J, Fujioka T, Furge KA, **Kort E**, Giraud S, Ferlicot S, Vielh P, Amsellem-Ouazana D, Debré B, Flam T, Thiounn N, Zerbib M, Benoît G, Droupy S, Molinié V, Vieillefond A, Tan PH, Richard S, Teh B. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. *BMC Cancer.* 2010 May 12;10:196.
39. **Kort EJ**, Croskey L, Scibienski T, Rajasekaran S, Jovinge S. Circulating Progenitor Cells and Childhood Cardiovascular Disease. *Pediatr Cardiol.* 2016 Feb;37(2):225-31
40. Rajasekaran S, **Kort E**, Hackbarth R, Davis AT, Sanfilippo D, Fitzgerald R, Zuiderveen S, Ndika AN, Beauchamp H, Olivero A, Hassan N. Red cell transfusions as an independent risk for mortality in critically ill children. *J Intensive Care.* 2016 Jan 7;4:2. doi: 10.1186/s40560-015-0122-3.
41. **Kort EJ**. Patent Ductus Arteriosus in the preterm infant: An update on mortality and morbidity. *Current Pediatric Reviews.* 2016;12(2):98-105.
42. Li G, Tian L, Goodyer W, **Kort EJ**, Buikema JW, Xu A, Wu JC, Jovinge S, Wu SM. Single cell expression analysis reveals anatomical and cell cycle-dependent transcriptional shifts during heart development. *Development.* 2019 Jun 14;146(12).
43. Mooney MR, Geerts D, **Kort EJ**, Bachmann AS. Anti-tumor effect of sulfasalazine in neuroblastoma. *Biochem Pharmacol.* 2019 Apr;162:237-249.
44. **Kort EJ**, Jovinge S. Streamlined analysis of LINCS L1000 data with the slinky package for R. *Bioinformatics.* 2019 Jan 10. [Epub ahead of print]
45. Milliron HY*, Weiland MJ*, **Kort EJ***, Jovinge S. Isolation of Cardiomyocytes Undergoing Mitosis With Complete Cytokinesis. *Circ Res.* 2019 Dec 6;125(12):1070-1086. doi: 10.1161/CIRCRESAHA.119.314908. Epub 2019 Oct 25. PMID: 31648614.
46. **Kort E**, Jovinge S. Drug Repurposing: Claiming the Full Benefit from Drug Development. *Curr Cardiol Rep.* 2021 May 7;23(6):62. doi: 10.1007/s11886-021-01484-5.
47. Gupta R, Leimanis ML, Adams M, Bachmann AS, Uhl KL, Bupp CP, Hartog NL, **Kort EJ**, Olivero R, Comstock SS, Sanfilippo DJ, Lunt SY, Prokop JW, Rajasekaran S. Balancing precision versus cohort transcriptomic analysis of acute and recovery phase of viral bronchiolitis. *Am J Physiol Lung Cell Mol Physiol.* 2021 Jun 1;320(6):L1147-L1157. doi: 10.1152/ajplung.00440.2020. Epub 2021 Apr 14.
48. Shankar R, Leimanis ML, Newbury PA, Liu K, Xing J, Nedveck D, **Kort EJ**, Prokop JW, Zhou G, Bachmann AS, Chen B, Rajasekaran S. Gene expression signatures identify paediatric patients with multiple organ dysfunction who require advanced life support in the intensive care unit. *EBioMedicine.* 2020 Dec;62:103122. doi: 10.1016/j.ebiom.2020.103122. Epub 2020 Nov 25.
49. Abdelsayed M, **Kort EJ**, Jovinge S, Mercola M. Repurposing drugs to treat cardiovascular disease in the era of precision medicine. *Nat Rev Cardiol.* 2022 Nov;19(11):751-764.

50. Tarnawski L, Shavva VS, **Kort EJ**, Zhuge Z, Nilsson I, Gallina AL, Martínez-Enguita D, Heller Sahlgren B, Weiland M, Caravaca AS, Schmidt S, Chen P, Abbas K, Wang FH, Ahmed O, Eberhardson M, Färnert A, Weitzberg E, Gustafsson M, Kehr J, Malin SG, Hult H, Carlström M, Jovinge S, Olofsson PS. Cholinergic regulation of vascular endothelial function by human ChAT+ T cells. Proc Natl Acad Sci U S A. 2023 Apr 4;120(14):e2212476120.

* denotes equal contribution by authors.

Other publications

1. Hadley A, Kort E, Wimberly K.Torres. Updates in pediatric sepsis. The Hospitalist. Sept , 2023.
<https://www.the-hospitalist.org/hospitalist/article/37502/pediatrics/updates-in-pediatric-sepsis/>

Not Retained